

Manzo Pharmaceuticals, Inc., Reports on Progress with Lacto-Freedom Probiotic

Milford, PA, August 22, 2016 -- Manzo Pharmaceuticals (OTCPink:MNZO) today reported that a New York based packaging company has started the second phase of manufacturing of Lacto-Freedom probiotic.

The patented Lacto-Freedom probiotic was manufactured in bulk by a GMP and FDA approved major US probiotic manufacturer and now, after additional testing, has been received by the New York based supplement manufacturer and they have started the manufacture of Lacto-Freedom probiotic. Ken Manzo, CEO of Manzo Pharmaceuticals, Inc. stated “We are slightly behind schedule with the manufacturing due to additional testing and quality controls to ensure the finest quality product.”

The supplement manufacturer will be diluting the probiotic to the proper dose, placing it into capsules, placing the capsules into bottles, and affixing the Lacto-Freedom labels on the bottles which will then be ready to be sold. The supplement manufacturer stated that it usually takes 8 to 10 weeks for a product to be completed from time of purchase order which was placed on August 9th, 2016. The new estimated date of release is early or mid October.

Ken Manzo also stated “We plan on selling the product initially on Amazon.com, and on our website as well after it is completely upgraded. We also plan on contacting physicians and let them know about the release of the product so they may recommend it to their patients. In addition, physicians may order the Lacto-Freedom probiotic by the case and sell it directly to their patients.”

More news to follow in another Press Release.

About Manzo Pharmaceuticals, Inc. Manzo Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, and testing of patented and non-patented solutions and remedies. Most

notable is a patented probiotic for lactose intolerance, and a natural sleep aid. For more information follow the company on twitter at @manzopharma, and visit www.manzopharma.com.

DISCLAIMER: This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information catered in this Press Release including such forward-looking statements.
